Welcome to the 4th ADC Analytical Development Summit
Ensure Regulatory Compliance Through a High-Quality ADC Product
The 4th ADC Analytical Development Summit is returning to Boston in April 2025. This event will bring together the brightest minds in the field to address the unique analytical challenges of antibody-drug conjugates. As regulatory expectations tighten and ADCs become increasingly complex, this summit will serve as your guide to ensuring high-quality products and seamless regulatory submissions.
With the FDA’s updated ICH Q14 guidance raising the bar for release and stability testing, adopting advanced analytical methods is more critical than ever to maintain product quality. This summit offers a unique platform to explore how to meet these regulatory requirements effectively while ensuring your ADC remains robust throughout its lifecycle.
ADC developers are increasingly working with novel payloads, linkers, and next-generation formats, such as multispecific conjugates and antibody-radio conjugates. These advancements introduce unprecedented complexity, requiring tailored analytical strategies to address challenges in DAR quantification, drug distribution analysis, and impurity profiling. This event delves into the methodologies needed to navigate these technical hurdles and adapt to the evolving ADC landscape.
The summit will also explore how cutting-edge analytical tools are being leveraged to enhance bioassays and improve potency measurement, providing deeper insights into ADC mechanisms of action. You’ll gain actionable strategies for refining impurity assays to quantify free drug and process-related impurities—critical for producing high-quality products that meet global regulatory standards.
Our World-Class Speaker Faculty Includes:
Coming Soon!
Previously Attending Companies Include:
Our Partners:
“It was a great time for pioneers in the ADC field to share their valuable experiences generously and meet people who sympathize with the analytical problems I face.” Manager, Kanaph Therapeutics